0001209191-20-003237.txt : 20200113 0001209191-20-003237.hdr.sgml : 20200113 20200113191534 ACCESSION NUMBER: 0001209191-20-003237 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200109 FILED AS OF DATE: 20200113 DATE AS OF CHANGE: 20200113 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Solomon Michael Edward CENTRAL INDEX KEY: 0001799320 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36694 FILM NUMBER: 20524725 MAIL ADDRESS: STREET 1: C/O ARTARA THERAPEUTICS, INC. STREET 2: 1 LITTLE WEST 12TH STREET CITY: NEW YORK STATE: NY ZIP: 10014 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ArTara Therapeutics, Inc. CENTRAL INDEX KEY: 0001359931 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 LITTLE WEST 12TH STREET CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: 646-844-0337 MAIL ADDRESS: STREET 1: 1 LITTLE WEST 12TH STREET CITY: NEW YORK STATE: NY ZIP: 10014 FORMER COMPANY: FORMER CONFORMED NAME: PROTEON THERAPEUTICS INC DATE OF NAME CHANGE: 20060420 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-01-09 0 0001359931 ArTara Therapeutics, Inc. TARA 0001799320 Solomon Michael Edward C/O ARTARA THERAPEUTICS 1 LITTLE WEST 12TH STREET NEW YORK NY 10014 1 0 0 0 Common Stock 2020-01-10 4 A 0 26500 0.00 A 26500 D Stock Option (Right to Buy) 9.18 2020-01-09 4 A 0 9537 A 2028-05-24 Common Stock 9537 9537 D Stock Option (Right to Buy) 9.18 2020-01-09 4 A 0 2861 A 2028-07-11 Common Stock 2861 2861 D Stock Option (Right to Buy) 9.18 2020-01-09 4 A 0 6676 A 2028-12-31 Common Stock 6676 6676 D Stock Option (Right to Buy) 9.18 2020-01-09 4 A 0 10491 A 2029-04-28 Common Stock 10491 10491 D The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of the Issuer's common stock. 50% of the shares vest on January 10, 2021 and 1/24th of the shares vest monthly thereafter. Settlement for the RSUs is deferred until the earliest to occur of (i) the Reporting Person's termination of service, (ii) death, (iii) disability and (iv) a change in control of the Issuer. In the event of a change in control of the Issuer, the RSUs will vest in full. On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. 1/48th of the shares subject to the option shall vest monthly following June 1, 2018, for so long as the Reporting Person provides continuous service to the Issuer. Received in the Merger in exchange for a stock option to acquire 50,000 shares of ArTara Sub common stock for $1.75 per share. 1/48th of the shares subject to the option shall vest monthly following August 1, 2018, for so long as the Reporting Person provides continuous service to the Issuer. Received in the Merger in exchange for a stock option to acquire 15,000 shares of ArTara Sub common stock for $1.75 per share. 1/48th of the shares subject to the option shall vest monthly following January 1, 2019, for so long as the Reporting Person provides continuous service to the Issuer. Received in the Merger in exchange for a stock option to acquire 35,000 shares of ArTara Sub common stock for $1.75 per share. 1/48th of the shares subject to the option shall vest monthly following April 29, 2019, for so long as the Reporting Person provides continuous service to the Issuer. Received in the Merger in exchange for a stock option to acquire 55,000 shares of ArTara Sub common stock for $1.75 per share. /s/ Jesse Shefferman, Attorney-in-fact 2020-01-13